Accounting for 15–20% of all breast carcinomas, triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2-receptor (HER2) [1]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.